Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Castle Biosciences Inc shares valued at $357,930 were sold by MAETZOLD DEREK J on Jun 27 ’25. At $20.30 per share, MAETZOLD DEREK J sold 17,632 shares. The insider’s holdings dropped to 3,615 shares worth approximately $71432.40000000001 following the completion of this transaction.
Also, MAETZOLD DEREK J sold 4,944 shares, netting a total of over 100,363 in proceeds. Following the sale of shares at $20.30 each, the insider now holds 69,683 shares.
Before that, Derek Maetzold had added 16,932 shares to its account. In a trade valued at $344,566, the Officer bought Castle Biosciences Inc shares for $20.35 each.
As published in their initiating research note from Guggenheim on December 14, 2023, Castle Biosciences Inc [CSTL] has been a Buy and the price target has been revised to $25. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in early January. As of January 07, 2022, Stephens has initiated its “an Overweight” rating for CSTL. Earlier on April 30, 2021, Lake Street initiated its rating. Their recommendation was “a Buy” for CSTL stock.
Analyzing CSTL Stock Performance
On last trading session, Castle Biosciences Inc [NASDAQ: CSTL] plunged -2.90% to $19.76. The stock’s lowest price that day was $19.14, but it reached a high of $20.7626 in the same session. During the last five days, there has been a surge of approximately 22.89%. Over the course of the year, Castle Biosciences Inc shares have dropped approximately -11.31%.
Is Castle Biosciences Inc subject to short interest?
Stocks of Castle Biosciences Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.16 million shares to 1.41 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 1.25 million shares. A jump of 11.46% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.4 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.4.
Which companies own the most shares of Castle Biosciences Inc (CSTL)?
In terms of Castle Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 33.5 in the next 12 months, up nearly 64.62% from the previous closing price of $20.35. Analysts anticipate Castle Biosciences Inc stock to reach 37 by 2025, with the lowest price target being 30. In spite of this, 3 analysts ranked Castle Biosciences Inc stock as Buy at the end of 2025. On November 10, 2020, KeyBanc Capital Markets assigned a price target of “an Overweight” to the stock and initiated coverage with a $70.
